CELGENE Corporation

? CELGENE Corporation Report

Industry:

Biotechnology & Pharmaceutical Innovation
(Focused on developing breakthrough therapies for cancer, inflammatory disorders, and other serious diseases) ??

Founded/Incorporated:

1986
(Celgene was established in 1986 and rapidly emerged as a leader in biopharma innovation.) ?

Headquarters:

86 Morris Avenue, Summit, NJ 07901, USA ??

Key Executives:

• • Pre-Acquisition Leadership:
    
    • • CEO: Mark Alles (historically led the company prior to the acquisition) ?
        (Note: Since the 2019 acquisition by Bristol Myers Squibb, executive leadership is integrated within BMS’s organizational framework.)

Employees:

(Prior to the acquisition, Celgene employed over 7,000 people globally. Current employee numbers are reflected in Bristol Myers Squibb’s consolidated workforce.) ?

Revenue & Financials:

• • Historical Revenue:
    Celgene consistently generated multi-billion-dollar revenues, with annual revenues exceeding $7 billion in its final years as an independent company. ?
    (Post-acquisition financials are consolidated within Bristol Myers Squibb’s reporting.)

Stock Information:

• • Pre-Acquisition:
    Listed on NASDAQ under the ticker symbol CELG.

• • Current Status:
    Celgene is now part of Bristol Myers Squibb, trading on the NYSE under the ticker symbol BMY. ?

Website:

www.celgene.com
(For the latest company information, please refer to Bristol Myers Squibb’s official communications.) ?

? Company Overview

CELGENE Corporation was a pioneering biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies targeting cancer and inflammatory disorders. Based in Summit, New Jersey, Celgene significantly advanced patient care through groundbreaking products and a robust research pipeline. In 2019, Celgene was acquired by Bristol Myers Squibb, a strategic move that enhanced global access to its innovative therapies while integrating its research capabilities into a larger pharmaceutical framework.

?️ Products & Services

Oncology Therapeutics ?

• • Multiple Myeloma & Hematologic Malignancies:
    Celgene revolutionized treatment paradigms with drugs such as Revlimid (lenalidomide), which played a pivotal role in managing multiple myeloma and other blood cancers.

• • Solid Tumor Treatments:
    The company expanded its portfolio to address various solid tumors through novel therapeutic agents.

Inflammatory & Immunology Solutions ?

• • Autoimmune Disorders:
    Beyond oncology, Celgene invested in therapies targeting autoimmune and inflammatory conditions, offering hope for diseases like rheumatoid arthritis and psoriasis.

Research & Development (R&D) Capabilities ?

• • Innovative Pipeline:
    With significant investment in R&D, Celgene developed a robust pipeline of next-generation therapies through clinical trials and strategic partnerships.

• • Biotechnology Platforms:
    Leveraging genomic insights and molecular targeting, Celgene’s platforms enabled the development of personalized medicine approaches.

? Corporate History & Milestones

• • Founding & Early Growth:
    Established in 1986, Celgene quickly rose to prominence by focusing on innovative drug discovery and development.

• • Breakthrough Therapies:
    The launch of Revlimid transformed the treatment landscape for multiple myeloma, establishing Celgene as a leader in oncology.

• • Strategic Expansion:
    Through a combination of organic growth and strategic acquisitions, Celgene broadened its therapeutic portfolio and market presence.

• • Acquisition by Bristol Myers Squibb (2019):
    The landmark acquisition consolidated Celgene’s innovative assets within a global pharmaceutical powerhouse, positioning the combined entity to accelerate the development of life-changing therapies.

? Global & Domestic Presence

• • Global Footprint:
    Prior to its acquisition, Celgene operated globally, with significant research, manufacturing, and commercial operations in North America, Europe, and Asia.

• • US Operations:
    The headquarters in Summit, NJ, served as a central hub for innovation, clinical development, and strategic decision-making.

• • Integration into Bristol Myers Squibb:
    Post-acquisition, Celgene’s operations have been seamlessly integrated, enhancing the combined entity’s ability to serve patients worldwide.

? Financial Highlights

• • Revenue Growth:
    Celgene consistently reported strong financial performance, driven by successful product launches and an expanding global market.

• • Investment in R&D:
    A significant portion of revenue was reinvested into research and development, fueling ongoing innovation and future pipeline growth.

• • Market Impact:
    The company’s financial success and strategic initiatives underscored its influential role in the biotechnology sector, culminating in its acquisition by Bristol Myers Squibb.

? Governance & Leadership

• • Executive Management:
    Under the leadership of former CEO Mark Alles and other key executives, Celgene was known for its visionary approach and operational excellence.

• • Corporate Governance:
    Celgene maintained rigorous governance standards, ensuring transparency and accountability throughout its operations.

• • Post-Acquisition Transition:
    Following the 2019 merger, Celgene’s governance and management practices have been integrated into Bristol Myers Squibb’s broader corporate structure.

? Recent News & Developments

• • Innovation & Pipeline Progress:
    Prior to the acquisition, Celgene’s pipeline was filled with promising candidates in oncology and immunology, attracting significant attention from the medical community.

• • Acquisition Milestone:
    The 2019 merger with Bristol Myers Squibb was a transformative event, reinforcing the combined entity’s commitment to innovation and patient care.

• • Strategic Focus:
    Post-acquisition, the integrated portfolio continues to drive advancements in targeted therapies, personalized medicine, and next-generation treatments. ?️?

? Sustainability & Innovation

CELGENE Corporation has been committed to:

• • Innovative Drug Development:
    Consistently investing in research to bring breakthrough therapies to market, transforming treatment landscapes for complex diseases. ??

• • Patient-Centric Focus:
    Dedicated to improving patient outcomes through personalized and targeted therapies.

• • Sustainable Healthcare Practices:
    Emphasizing ethical research, efficient manufacturing, and long-term value creation for patients and stakeholders. ♻️

? Conclusion

CELGENE Corporation has been a pioneer in the biotechnology industry, renowned for its innovative approaches to treating cancer and inflammatory disorders. With a rich history of groundbreaking therapies and strong financial performance, Celgene set new standards in biopharmaceutical innovation. Now integrated into Bristol Myers Squibb, its legacy continues to drive forward the development of life-changing treatments on a global scale. For the most comprehensive and up-to-date information, stakeholders are advised to consult official Bristol Myers Squibb disclosures and industry communications. ??